South African billionaire Saltzman family’s Dis-Chem stake gains $21 million
The $21.08-million increase in the market value of the Saltzman family’s stake in Dis-Chem solidifies their position as significant investors on the JSE.
Skip to content
The $21.08-million increase in the market value of the Saltzman family’s stake in Dis-Chem solidifies their position as significant investors on the JSE.
Thanks to the recent upswing in Dis-Chem’s shares, the Saltzman family’s stake in Dis-Chem has surged by R776.36 million ($41.42 million) since Feb. 19.
The sell-off, a routine measure to trim his stakes in the leading group, follows Saltzman’s decision to step down as the CEO in June 2023.
By owning these critical assets outright, Dis-Chem aims to enhance its operational efficiency and ensure long-term strategic stability.
The market value of the Saltzman family’s joint stake in Dis-Chem Pharmacies has declined from $487.7 million on Jan. 1 to $465.61 million.
Lynette and Ivan Saltzman own a beneficial 35.12-percent stake in the Gauteng-based Dis-Chem Pharmacies.
Since the Saltzmans founded Dis-Chem Pharmacies more than four decades ago, it has grown into one of the country’s leading retail healthcare groups.
Saltzman and his wife own a 35.12-percent stake in Dis-Chem Pharmacies, a Gauteng-based retail pharmacy chain.
Lynette and Ivan Saltzman, who established Dis-Chem Pharmacies in 1978, presently hold a beneficial 35.15-percent stake in the healthcare giant.
Saltzman, along with his wife Lynette, co-founded Dis-Chem Pharmacies in 1978.
Dis-Chem’s founder and long-time steps down; CFO Rui Morais to become CEO in July.
The Saltzman family owns a beneficial 45.2-percent stake in Dis-Chem Pharmacies.
Dis-Chem Pharmacies is a high-performing pharmacy and healthcare group in South Africa.
Over the years, Dis-Chem Pharmacies has grown into one of South Africa’s leading retail healthcare groups.
The payment will be made as part of the healthcare firm’s insurance coverage in South Africa.
The Saltzman family owns a beneficial 45.2-percent share in the healthcare company.